Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis
- PMID: 34798454
- PMCID: PMC8542448
- DOI: 10.1016/j.ejca.2021.10.013
Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis
Abstract
Background: Efficacy and safety data of COVID-19 vaccines among cancer populations have been limited; however, preliminary data from recent studies have emerged regarding their immunogenicity and safety in this population. In this review, we examined current peer-reviewed publications containing serological and safety data after COVID-19 vaccination of patients with cancer.
Methods: This analysis examined 21 studies with a total of 5012 patients with cancer, of which 2676 (53%) had haematological malignancies, 2309 (46%) had solid cancers and 739 were healthy controls. Serological responses by anti-SARS-CoV-2 spike protein S1/S2 immunoglobulin G antibody levels and post-vaccination patient questionnaires regarding vaccine-related side-effects after the first and second dose were collected and analysed.
Results: In general, a single dose of the COVID-19 vaccine yields weaker and heterogeneous serological responses in both patients with haematological and solid malignancies. On receiving a second dose, serological response rates indicate a substantial increase in seropositivity to the SARS-CoV-2 spike protein in all cancer cohorts, but antibody titres remain reduced in comparison with healthy controls. Furthermore, seroconversion in patients with haematological malignancies was significantly lower than that in patients with solid tumours. COVID-19 vaccines are safe and well-tolerated in patients with cancer based on current data of local and systemic effects.
Conclusion: Together, these data support the prioritisation of patients with cancer to receive their first and second doses to minimise the risk of COVID-19 infection and severe complications in this vulnerable population. Additional prophylactic measures must be considered for high-risk patients where current vaccination programs may not mount sufficient protection against SARS-CoV-2 infection.
Keywords: COVID-19; COVID-19 vaccines; Immunity; Neoplasms; SARS-CoV-2; Seroconversion.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Conflict of interest statement The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article.
Figures


References
-
- WHO Coronavirus Disease (COVID-19) Dashboard 2021. https://covid19.who.int/
-
- Scarfò L., Chatzikonstantinou T., Rigolin G.M., Quaresmini G., Motta M., Vitale C., et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. 2020;34:2354–2363. doi: 10.1038/s41375-020-0959-x. - DOI - PMC - PubMed
-
- Cook G., John Ashcroft A., Pratt G., Popat R., Ramasamy K., Kaiser M., et al. Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy. Br J Haematol. 2020;190:e83–e86. doi: 10.1111/bjh.16874. - DOI - PMC - PubMed
-
- Hultcrantz M., Richter J., Rosenbaum C.A., Patel D., Smith E.L., Korde N., et al. COVID-19 infections and clinical outcomes in patients with multiple myeloma in New York city: a cohort study from five academic centers. Blood Cancer Discov. 2020;1:234–243. doi: 10.1158/2643-3230.bcd-20-0102. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous